Abstract
Permanent remissions have been attained in Crohn’s disease. Nevertheless, the current focus of therapy remains sclerosed with the prevailing drug therapy through which temporary remissions are attainable. FDA’s reliance on evidence-based validation through comparative, placebo controlled, double-blinded studies has created an impediment to acceptance of divergent alternated therapies as being within the standard of care. In so doing, FDA has basically surrendered the therapeutic dialogue of Crohn’s disease to those who can pay for such studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have